“Quintiles and DaVita Clinical Research have entered into a global strategic alliance to deliver a differentiated clinical trial offering (Phase II-IV) to biopharmaceutical customers in renal disease trials,” Jeanne Hecht, SVP and Global Head, Site & Patient Networks at Quintiles, told Outsourcing-Pharma.com.
Through the alliance, Quintiles will gain access to DaVita’s clinical care experience and research sites.
“By leveraging Quintiles’ protocol modeling and feasibility, in combination with DaVita Clinical Research’s extensive patient understanding, biopharmaceutical customers will be able to leverage the combined assets of both companies to progress their clinical programs,” said Hecht.
Additionally, Hecht said that aligned operational procedures and historical site performance metrics will enable faster site start-up and more predictable patient enrollment.
“Nephrology clinical studies can pose a series of challenges from progressively complex protocol designs to an increasing demand for broad patient population participation,” added Hecht. “Through this alliance, we may also be able to alleviate the burden on patients participating in trials by incorporating clinical research into clinical care.”